Credit: Getty Images Researchers assessed patients with uncomplicated urinary tract infections to determine factors associated with extended-spectrum β-lactamase-producing uropathogens.

Intravenous cefepime-zidebactam was significantly superior to meropenem in phase III trial ...

Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales have emerged as leading causes of urinary tract infections in children worldwide, undermining the efficacy of many first-line ...

Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...

Urinary tract infections (UTIs) rank among the most prevalent bacterial infections worldwide, affecting an estimated 150 million individuals annually. While simple cystitis in otherwise healthy ...